d-Dimer trend in a long-term rheumatoid arthritis patient with tofacitinib treatment and recent COVID-19 infection

The SARS-CoV-2 virus was first identified in December 2019, the infection was named COVID-19. The initial symptoms and evolution of the disease have been described over the past year. The virus has been shown to increase the risk of thromboembolic events due to the hypercoagulable state triggered by...

Descripción completa

Detalles Bibliográficos
Autores principales: Maldonado, Genessis, Guerrero, Roberto, Intriago, Maria, Rios, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255109/
http://dx.doi.org/10.1016/j.rcreu.2021.06.003
_version_ 1783717842944786432
author Maldonado, Genessis
Guerrero, Roberto
Intriago, Maria
Rios, Carlos
author_facet Maldonado, Genessis
Guerrero, Roberto
Intriago, Maria
Rios, Carlos
author_sort Maldonado, Genessis
collection PubMed
description The SARS-CoV-2 virus was first identified in December 2019, the infection was named COVID-19. The initial symptoms and evolution of the disease have been described over the past year. The virus has been shown to increase the risk of thromboembolic events due to the hypercoagulable state triggered by systemic endothelial inflammation. We present the case of a patient with a history of rheumatoid arthritis under prolonged treatment with tofacitinib, who presented COVID-19 and subsequently developed a hypercoagulable state of approximately 6 months’ duration. The possible association between viral infection and the use of tofacitinib is debated.
format Online
Article
Text
id pubmed-8255109
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U.
record_format MEDLINE/PubMed
spelling pubmed-82551092021-07-06 d-Dimer trend in a long-term rheumatoid arthritis patient with tofacitinib treatment and recent COVID-19 infection Maldonado, Genessis Guerrero, Roberto Intriago, Maria Rios, Carlos Revista Colombiana de Reumatología Case Report The SARS-CoV-2 virus was first identified in December 2019, the infection was named COVID-19. The initial symptoms and evolution of the disease have been described over the past year. The virus has been shown to increase the risk of thromboembolic events due to the hypercoagulable state triggered by systemic endothelial inflammation. We present the case of a patient with a history of rheumatoid arthritis under prolonged treatment with tofacitinib, who presented COVID-19 and subsequently developed a hypercoagulable state of approximately 6 months’ duration. The possible association between viral infection and the use of tofacitinib is debated. Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. 2022-06 2021-07-05 /pmc/articles/PMC8255109/ http://dx.doi.org/10.1016/j.rcreu.2021.06.003 Text en © 2021 Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Case Report
Maldonado, Genessis
Guerrero, Roberto
Intriago, Maria
Rios, Carlos
d-Dimer trend in a long-term rheumatoid arthritis patient with tofacitinib treatment and recent COVID-19 infection
title d-Dimer trend in a long-term rheumatoid arthritis patient with tofacitinib treatment and recent COVID-19 infection
title_full d-Dimer trend in a long-term rheumatoid arthritis patient with tofacitinib treatment and recent COVID-19 infection
title_fullStr d-Dimer trend in a long-term rheumatoid arthritis patient with tofacitinib treatment and recent COVID-19 infection
title_full_unstemmed d-Dimer trend in a long-term rheumatoid arthritis patient with tofacitinib treatment and recent COVID-19 infection
title_short d-Dimer trend in a long-term rheumatoid arthritis patient with tofacitinib treatment and recent COVID-19 infection
title_sort d-dimer trend in a long-term rheumatoid arthritis patient with tofacitinib treatment and recent covid-19 infection
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255109/
http://dx.doi.org/10.1016/j.rcreu.2021.06.003
work_keys_str_mv AT maldonadogenessis ddimertrendinalongtermrheumatoidarthritispatientwithtofacitinibtreatmentandrecentcovid19infection
AT guerreroroberto ddimertrendinalongtermrheumatoidarthritispatientwithtofacitinibtreatmentandrecentcovid19infection
AT intriagomaria ddimertrendinalongtermrheumatoidarthritispatientwithtofacitinibtreatmentandrecentcovid19infection
AT rioscarlos ddimertrendinalongtermrheumatoidarthritispatientwithtofacitinibtreatmentandrecentcovid19infection

Ejemplares similares